Advanced Medical Solutions ends year in line, agrees Austria acquisition

Advanced Medical Solutions (AMS) reported “strong” financial performance in line with expectations in its preliminary results on Wednesday, and announced a deal to acquire the Austria-based distributor AFS Medical.

  • Advanced Medical Solutions Group
  • 28 March 2024 17:21:04
Advanced Medical Solutions

Source: Sharecast

The AIM-traded firm said its revenue increased to £108.6m for the year ended 31 December, up from £86.8m in 2020, with “strong performances” across its key product categories and territories as elective surgery levels and wound treatment volumes rebounded towards pre-pandemic levels.

It represented an increase of 25% on a reported basis, and 29% on a constant currency basis.

Adjusted profit before tax grew 92% year-on-year to £25.6m, as increased sales volumes drove “significant improvements” in operational leverage.

Net cash increased to £73m from £53.8m, which the board said was driven by “strong trading” during the year, and “robust” operational cash flow.

Investment in research and development increased to £9.3m from £7.9m, representing 8.6% of revenues, down from 9.1% in the prior year, as progress continued across the group’s key projects.

AMS said revenue in its surgical business unit increased to £64.6m from £50.2m, which was an increase of 34% at constant currency, while revenues in wound care rose to £44m from £36.6m, which was a constant currency increase of 23%.

Sales of ‘Global LiquiBand improved to £33.1m from £22.8m - an increase of 53% at constant currency - with the firm reporting “particular strength” in the United States market, as end user demand returned and its partners rebuilt inventories.

Reflecting the “strong” performance and its confidence in the group's outlook, the board proposed an increased final dividend of 1.37p per share, up from 1.2p at the end of 2020.

AMS also announced an agreement to acquire AFS Medical on Wednesday - an Austria-based distributor of minimally-invasive surgical devices including ‘LiquiBandFix8’.

The company said the deal was expected to complete in mid-2022, subject to regulatory clearances, and would strengthen iots direct surgical sales footprint and capabilities

“The acquisition of AFS enhances our direct selling footprint and capabilities, product portfolio and our plans to increase Fix8 penetration globally and I am delighted to welcome them to the group,” said chief executive officer Chris Meredith.

“Despite the pandemic continuing to present challenges, trading has started well in the new financial year and I remain confident that our commitment to innovation, investment in research and development and the expansion of our distribution network will deliver significant and robust long-term growth.”

At 1232 GMT, shares in Advanced Medical Solutions Group were down 1.92% at 281.5p.

N/A

Isin: N/A
Exchange: N/A
Sell:
N/A
Buy:
N/A
Change:
Date:
Prices delayed by at least 15 minutes

Compare our accounts

Whether you're looking for a Share Dealing Account or Share Dealing ISA, we've got an account to suit your needs.

Lloyds Bank is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.

Important legal information

The Lloyds Bank Direct Investments Service is operated by Halifax Share Dealing Limited. Registered Office: Trinity Road, Halifax, West Yorkshire, HX1 2RG. Registered in England and Wales no. 3195646. Halifax Share Dealing Limited is authorised and regulated by the Financial Conduct Authority, 12 Endeavour Square, London, E20 1JN under registration number 183332. A Member of the London Stock Exchange and an HM Revenue & Customs Approved ISA Manager.

Logo Allfunds

The information contained within this website is provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd unless otherwise stated. The information is not intended to be advice or a recommendation to buy, sell or hold any of the shares, companies or investment vehicles mentioned, nor is it information meant to be a research recommendation. This is a solution powered by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd incorporating their prices, data news, charts, fundamentals and investor tools on this site. Terms and conditions apply. Prices and trades are provided by Allfunds Digital, S.L.U. acting through its business division Digital Look Ltd and are delayed by at least 15 minutes.

FE fundinfo Logo

Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

Refinitiv Logo

© 2024 Refinitiv, an LSEG business. All rights reserved.